Performance | Geographical Review Geographical Review This section contains further information about the performance of our products within the geographical areas in which our sales and marketing efforts are focused.
2012 in brief Emerging Markets sales increased by and details of relevant risks are set out in In the US, sales were down 21% to 4% to $5,752 million 2011: $5,763 million: the Principal risks and uncertainties section $10,655 million 2011: $13,426 million: 2010: $5,198 million with sales growth in from page 75.
See the Market denitions 2010: $13,727 million.
Loss of exclusivity China of 17% and also in Russia of 17%.
table on page 209 for information about on Seroquel IR in March 2012 as well AstraZenecas market denitions.
Sales 2011 in brief as the impact of increased generic gures in this Geographical Review are In the US, sales were down 2% to $13,426 with reference to the customers location.
competition experienced by our other million 2010: $13,727 million.
The pricing mature brands was partially offset by impact from US healthcare reform US strong performance from our key brands, measures lowered revenue by around AstraZeneca is the fourth largest Brilinta, Crestor, Onglyza, Symbicort 3.3%.
Good growth for Crestor, the pharmaceutical company in the US, with and Faslodex.
Seroquel franchise, Symbicort and a 5% market share of US pharmaceuticals AstraZeneca is the fourth largest Onglyza, broadly offset the impact of by sales value.
pharmaceutical company in the US, with generic competition for Arimidex, Toprol-XL Sales in the US decreased by 21% to a 5% market share of US pharmaceuticals and Merrem, and declines in Nexium.
Sales in Western Europe were down $13,727 million, as strong performance AstraZeneca is the eighth largest 11% to $8,501 million 2010: $9,168 from our key brands, Brilinta, Crestor, prescription-based pharmaceutical million, due largely to volume erosion Onglyza, Symbicort and Faslodex, was company in Western Europe, with on Nexium, Arimidex and Meronem.
offset by loss of exclusivity on Seroquel IR a 3.4% market share of sales by value.
This was partially offset by volume in March 2012 as well as the impact of Sales in Western Europe were down 19% growth attributable to Crestor, Seroquel increased generic competition experienced to $6,486 million 2011: $8,501 million: XR, Symbicort, Iressa and Faslodex.
by our other mature brands.
Key drivers of the Established ROW sales were up sales of our key brands, Brilinta, Crestor, decline were the volume erosion on 4%, driven by continued growth of Onglyza, Symbicort and Faslodex, Atacand, Seroquel IR, Nexium, Arimidex Symbicort, Crestor, Nexium and the were up by 9% to $4,733 million 2011: and Meronem, following entry of generic Seroquel franchise.
In 2011, AstraZeneca competition and the negative price and $4,351 million: 2010: $3,569 million.
became the largest research-based volume impact primarily related to Other drivers of the sales decline pharmaceutical company in Canada government interventions, particularly include the reduction of sales for Zomig by sales value.
in Greece, Italy, Portugal and Spain.
following the licensing of Zomig to Impax Emerging Markets sales increased by This development was partially offset by Pharmaceuticals Inc. in February 2012 10% to $5,763 million 2010: $5,198 revenue growth from Brilique, Onglyza, down to $12 million 2011: $158 million: million, with sales growth in China of 15% Vimovo and Iressa.
2010: $176 million, additional generic and Russia of 19%.
Sales in Brazil were Established ROW sales were down 14%.
competition affecting sales of Toprol-XL down as a result of generic competition The entry of generic competition of down to $320 million 2011: $404 million: for Crestor and Seroquel IR.
Crestor in Canada, and Seroquel IR and 2010: $689 million, and loss of exclusivity Arimidex in Australia was partially offset For more information regarding our of Atacand down to $150 million 2011: by the successful first full year of launch products, see the Therapy Area Review $182 million: 2010: $216 million.
of Nexium and Faslodex in Japan.
Details of material legal Brilinta achieved sales of $19 million.
proceedings can be found in Note 25 Commercial preferred unrestricted to the Financial Statements from page 184 managed markets access was 54% Our financial performance 2012 2011 2010 Reported CER Reported CER Sales growth growth Sales growth growth Sales $m % % $m % % $m US 10,655 21 21 13,426 2 2 13,727 Western Europe 6,486 24 19 8,501 7 11 9,168 Canada 1,090 32 31 1,604 6 1 1,510 Japan 2,904 5 5 3,064 17 6 2,617 Other Established ROW 1,086 12 12 1,233 18 4 1,049 Established ROW 5,080 14 14 5,901 14 4 5,176 Emerging Europe 1,165 6 2 1,244 7 7 1,165 China 1,512 20 17 1,261 20 15 1,047 Emerging Asia Pacic 923 5 3 968 9 5 890 Other Emerging ROW 2,152 6 2,290 9 12 2,096 Emerging Markets 5,752 4 5,763 11 10 5,198 Total 27,973 17 15 33,591 1 2 33,269 70 AstraZeneca Annual Report and Form 20-F Information 2012 Overview Strategy Performance Corporate Governance Financial Statements Additional Information and trial among target interventional Nexium was the third most prescribed potential consequences of the Affordable cardiologist initiators was 39% at the end branded pharmaceutical in the US.
In the Care Act or related legislative changes when of 2012.
Crestor demonstrated resilience face of continuing generic, OTC and pricing taken together with the number of other in the face of the November 2011 market pressures, Nexium sales declined 5% to market and industry-related factors that can entry of a generic version and, from May, $2,272 million 2011: $2,397 million: 2010: also result in similar impacts.
Further details multiple generic versions of atorvastatin, all $2,695 million.
Nexium remains the branded on the impact of the Affordable Care Act competitors of Crestor.
Crestors performance market leader retaining significant market are contained in the Pricing pressure section volume showed resilience in two of the share and volume within the proton pump from page 18 and the Principal risks and uncertainties section from page 75. largest and most profitable segments inhibitor class.
of the market, Commercial and Medicare.
In 2012, sales of Synagis were up 7% Currently, there is no direct governmental Crestors existing patient base remained to $611 million 2011: $570 million: control of prices for commercial prescription solid, and continuing patients represented 2010: $646 million.
Sales in the 2011 drug sales in the US.
However, some 94% of Crestors volume.
Crestor achieved to 2012 RSV season experienced payer publicly funded programmes, such as sales of $3,164 million 2011: $3,074 million: pressure, which was offset by heightened Medicaid and TRICARE Department of 2010: $2,640 million and a total prescription awareness efforts surrounding the RSV Veterans Affairs, have statutorily mandated share of 11.8% within the statin market.
In burden of disease, appropriate patient rebates and discounts that have the effect 2012, Crestor became the most prescribed identication and enhanced efforts to of price controls for these programmes.
branded pharmaceutical in the US.
ensure continuity of care for patients from Additionally, pressure on pricing, availability Symbicort pMDI continued to deliver the hospital to the paediatricians ofce.
and utilisation of prescription drugs for both steady growth in the US with sales up 19% commercial and public payers continues In March 2010, the Affordable Care Act to $1,003 million 2011: $846 million: 2010: to increase.
This is driven by, among other came into force.
It has had, and is expected $721 million and prescription growth of things, an increased focus on generic to continue to have, a significant impact 12.5%.
It achieved a 21.3% total prescription alternatives.
Primary drivers of increased on our US sales and the US healthcare share and a 22.5% new prescription share generic use are budgetary policies within industry as a whole.
In 2012, the overall of the inhaled corticosteroid long-acting healthcare systems and providers, including reduction in our profit before tax for the betaagonist market.
the use of generics only formularies, 2 year due to higher minimum Medicaid and increases in patient co-insurance Following the completion of BMSs acquisition rebates on prescription drugs, discounts or co-payments.
In 2012, 84% of the of Amylin, AstraZeneca and BMS have been on branded pharmaceutical sales to prescriptions dispensed in the US were developing and commercialising Amylins Medicare Part D beneciaries and an generic.
While it is unlikely that there will portfolio of products related to diabetes industry-wide excise fee was $858 million.
be widespread adoption of a broad national and other metabolic diseases.
Sales of This amount reects only those effects price control scheme in the near future, there GLP-1 agonists for the treatment of diabetes of the Affordable Care Act that we know will continue to be increased attention to were $74 million for Byetta, $37 million have had or will have a direct impact pharmaceutical prices and their impact on for Bydureon and $17 million for Symlin.
on our financial condition or results of healthcare costs for the foreseeable future.
operations and which we are therefore Onglyza Kombiglyze XR captured more able to quantify based on known and Rest of World than one in five new DPP-IV patient isolatable resulting changes in individual Sales performance outside the US in treatment decisions and achieved a 2.8% financial items within our Financial 2012 was down by 11% to $17,318 million total prescription market share gain in 2012, Statements.
There are other potential 2011: $20,165 million: 2010: $19,542 million, ending the year with a total prescription indirect or associated consequences due to loss of exclusivity, competition market share of 17.1% of the rapidly of these legislative developments, which from generic products and the continuing growing DPP-IV inhibitor market.
Onglyza continue to evolve and which cannot challenging economic environment.
revenues in the US were $237 million be estimated but could have similar Combined sales of key products Arimidex, 2011: $156 million: 2010: $54 million.
These include broader changes Crestor, Nexium, Seroquel IR and Seroquel The loss of exclusivity for Seroquel IR in in access to or eligibility for coverage under XR, and Symbicort were down 11% with March 2012 resulted in a decrease in sales Medicare, Medicaid or similar governmental sales of $8,769 million 2011: $10,301 million: of 79% to $697 million 2011: $3,344 million: programmes, such as the recent proposals 2010: $9,923 million.
In 2012, generics to limit Medicare benets.
These could delivered strong sales, up 4% with sales accounted for 58.5% of quetiapine indirectly impact our pricing or sales of of $5,752 million 2011: $5,763 million: prescriptions in the US.
The presence prescription products within the private 2010: $5,198 million.
of generic competition impacted the sector.
By their nature and the fact that these Western Europe prescription volume of Seroquel XR in 2012. potentially numerous consequences are AstraZeneca is the eighth largest However, sales of Seroquel XR were up 4% not directly linked to a corresponding pharmaceutical company in Western to $811 million 2011: $779 million: 2010: and quantiable impact on our Financial Europe, with a 3.4% market share $640 million because of higher prices.
Statements, it is not possible to accurately of prescription sales by value.
estimate the financial impact of these AstraZeneca Annual Report and Form 20-F Information 2012 71 Performance | Geographical Review The macro-economic situation has In the UK, a 22% decrease in sales to Nexium, Symbicort, Seroquel IR and Seroquel XR were $742 million deteriorated, particularly in Greece, Italy, $668 million 2011: $866 million: 2010: 2011: $1,171 million: 2010: $1,055 million.
Portugal and Spain which have seen the $1,022 million reected strong volume implementation of new austerity measures, erosion on Seroquel IR and Seroquel XR Japan leading to increased pressure on healthcare sales declined to $58 million: 2011: $120 Sales in Japan decreased by 5% to budgets.
Most governments in Europe million: 2010: $124 million, following generic $2,904 million 2011: $3,064 million: intervene directly to control the price, volume entrants.
Sales of Nexium decreased by 2010: $2,617 million.
Strong performance and reimbursement of medicines.
Several 59% to $17 million 2011: $41 million: 2010: from Crestor, Symbicort, Faslodex and governments have imposed price reductions $89 million and sales of Arimidex decreased Iressa was largely offset by biennial price and increased the use of generic medicines by 85% to $4 million 2011: $28 million: cuts imposed in April 2012. as part of healthcare expenditure control.
2010: $114 million, both following the impact Crestor sales grew by 4%, becoming the A number of countries are applying strict of a full year of generic penetration.
The number one brand in the statin market in criteria for cost-effectiveness evaluations of decrease in UK sales was partially offset by Japan.
Symbicort sales grew 12%, backed medicines, which has delayed and reduced the solid performance of Symbicort, up 6% by additional therapeutic indications for access to medicines for patients in areas to $328 million 2011: $312 million: 2010: $272 million.
of important unmet medical need.
These and other measures all contribute to Nexium achieved sales of $78 million Sales in France decreased by 18% to an increasingly difficult environment for in its first full year after launch, with sales $1,314 million 2011: $1,740 million: 2010: branded pharmaceuticals in Europe.
accelerating following the lifting in October $1,889 million, driven largely by volume of the two week prescription limit imposed Total sales in Western Europe were down erosion on Nexium, Atacand, Zomig and by the Japanese Ministry of Health, Labour 19% to $6,486 million 2011: $8,501 million: Arimidex, following generic entrants, and and Welfare on new medicines during 2010: $9,168 million due largely to volume the impact from the disposal of Astra Tech, the first year from launch.
erosion on Seroquel IR, Nexium, Arimidex which was not entirely offset by the strong and Meronem following generic entrants growth of Crestor and the successful launch Our oncology business remains one of the and the negative price and volume impact of Seroquel XR, which had sales of $37 leaders in Japan based on the performance primarily related to government interventions, million.
Sales in Spain and Italy were down of established brands including Iressa, particularly in Greece, Italy, Portugal and by 22% to $510 million 2011: $708 million: Arimidex, Zoladex and Casodex.
The loss of exclusivity for Atacand 2010: $788 million and by 15% to $876 launched in November 2011, achieved sales in April 2012 resulted in a decrease in sales million 2011: $1,113 million: 2010: $1,198 of $58 million in its first full year in the market.
of 39% to $422 million 2011: $731 million: million, respectively, mainly driven by Other Established ROW 2010: $736 million.
Generics now account generic entrants and the implementation of Our sales in Other Established ROW for 9.7% of candesartan prescriptions in price and prescription controls associated showed a decline of 12% to $1,086 million Western Europe.
This development was with existing and new austerity measures.
partially offset by revenue growth attributable Established ROW Australian sales were impacted by price to Brilique, Onglyza, Vimovo and Iressa.
Sales in Established ROW decreased by cuts triggered by loss of exclusivity of Crestor outperformed the statin class with 14%.
The key products with sales growth Seroquel IR and Arimidex in April 2012, strong 2% sales growth.
Generic versions in 2012 were Symbicort, Seroquel XR, as well as by price reductions due to of Seroquel IR are now available in Western Onglyza, Faslodex and Iressa.
the Australian governments therapeutic Europe, with overall sales down 56% to Canada group policy, which impacted Crestor $226 million 2011: $546 million: 2010: The trend in Canada indicates that and Atacand.
provinces will continue to introduce policy partially offset by performance of Crestor, Brilique has been launched in all markets changes that drive cost savings and exert Nexium and Symbicort, which all gained in Western Europe and sales reached pricing pressure on new and existing market share.
Crestor achieved a 28.1% volume share in the statin class and became $55 million in 2012 2011: $9 million.
medicines for example, conditional listings, the number one drug in the statin market product listing agreements and bulk In Germany, sales fell by 30% to $775 million in Australia following loss of exclusivity purchasing, while providing reasonable 2011: $1,189 million: 2010: $1,235 million, of atorvastatin.
Brilinta was successfully patient access to innovative medicines.
mainly driven by market entries of generic launched in Australia with reimbursement versions of Atacand sales declined to Due to the loss of exclusivity for Crestor through the Australian pharmaceutical $141 million: 2011: $255 million: 2010: in Canada in April 2012, and the continued benets scheme becoming available from $252 million, Seroquel IR sales declined impact of the at risk launch of a generic August.
Brilinta achieved formulary listing to $31 million: 2011: $127 million: 2010: version of Nexium by a competitor in 2011, in the vast majority of hospitals in Australia $113 million and Seroquel XR sales declined total Canadian sales decreased by 31% to in 2012.
Marketing authorisation was to $93 million: 2011: $151 million: 2010: $1,090 million 2011: $1,604 million: 2010: obtained for Symbicort pMDI in Australia.
Combined sales of Crestor, 72 AstraZeneca Annual Report and Form 20-F Information 2012 Overview Strategy Performance Corporate Governance Financial Statements Additional Information Crestor continues to face challenges from China The Latin American pharmaceutical generic competitors.
The patent protecting Our sales in China excluding Hong Kong market continues to grow, underpinned Crestor in Australia has been challenged.
increased by 17% to $1,512 million 2011: by a reasonably stable political and Details of this matter are included in Note 25 $1,261 million: 2010: $1,047 million.
However, in many of the countries, the majority of the to the Financial Statements from page 184. of products in our Cardiovascular and growth in the market is being captured Respiratory & Inammation Therapy Areas Emerging Markets by generics, branded generics and private continue to grow ahead of the market, In Emerging Markets, our sales increased label product offerings, often from local, driven by strong performances of Crestor, by 4% to $5,752 million 2011: $5,763 million: non-multinational, companies.
Betaloc Zok and Pulmicort Respules.
2010: $5,198 million, which was principally Sales of Nexium and Symbicort grew driven by growth in China and Russia.
In Latin America, our sales were down strongly by 27% and 50% respectively, 1% to $1,331 million 2011: $1,455 million: In many of the larger markets, such as while our mature gastrointestinal and 2010: $1,392 million.
This was driven by Brazil and Mexico, patients tend to pay oncology brands experienced challenges declines in Mexico, down 22%, and Brazil, directly for prescription medicines and from government pricing reductions.
Brazil continued to feel the consequently these markets are at less In 2012, we saw Zoladex 10.8mg effects of the loss of exclusivity on Seroquel risk of direct government interventions successfully launched in China, the IR and Crestor with year-on-year declines on pricing and reimbursement.
In other expansion of our co-promotion with of 54% and 39% respectively.
Growth markets such as South Korea, Taiwan BMS to achieve listing of Onglyza into key of Seloken, Faslodex and older products and Turkey, where governments pay for hospitals, and a new collaboration formed such as Diprivan and Meronem helped medicines, we are seeing continued efforts between AstraZeneca and Ironwood to compensate for this development.
to reduce the cost of prescriptions in line to co-develop and co-commercialise In Mexico, challenging market conditions with the systems in Western Europe, Canada linaclotide in China.
We continue to be one and the impact of an at risk generic version and Australia.
Some strong growth markets of the leading multinational pharmaceutical of Crestor, resulted in weak performance such as Vietnam are also implementing companies in China.
with sales in Mexico declining by 22%.
price and volume controls in an attempt Emerging Asia Pacic This was partially offset by sales growth to control government spending.
Sales in Emerging Asia Pacic decreased in Venezuela up 41% and Argentina Emerging Europe by 3% to $923 million 2011: $968 million: up 24%.
All key brands achieved double Sales in Emerging Europe grew by 2% 2010: $890 million.
This decline was driven digit growth in Argentina Nexium, Crestor, to $1,165 million 2011: $1,244 million: by India, where sales decreased by 29% Atacand, Symbicort and Seroquel XR 2010: $1,165 million driven by increased to $67 million 2011: $110 million: 2010: and growth of more than 40% in Venezuela sales in Russia and Romania, which $92 million, due primarily to supply issues: Crestor, Symbicort, Seroquel XR, Atacand, more than offset reduced sales in Turkey.
continued government interventions on Zoladex and Arimidex.
pricing in countries such as Thailand, We have continued to build our presence Successful product launches in the year where sales decreased by 7% to $97 million in Russia, where sales increased by 17% included Brilinta and Kombiglyze XR in 2011: $106 million: 2010: $114 million : to $314 million 2011: $284 million: 2010: Mexico, Colombia and Argentina, and and by Vietnam, where sales decreased $232 million mainly due to increased sales Vimovo in Brazil, Colombia and Argentina.
by 4% to $45 million 2011: $47 million: of Symbicort by 24%, Nexium by 93%, Faslodex 500mg was launched in the 2010: $37 million.
This was partially offset Crestor by 14% and Seroquel XR by 154%, fourth quarter of 2012 in Argentina, and by sales growth in Indonesia, up 7% to driven by growth in the retail segment.
is expected to launch in the first half $39 million 2011: $39 million: 2010: $34 We have also consolidated our position of 2013 in Brazil and Venezuela.
million : South Korea, up 4% to $239 million among the growth leaders in the hospital In the Middle East and Africa, despite 2011: $235 million: 2010: $213 million : and regional reimbursement segments.
political challenges arising from the Arab and Malaysia, up 6% to $73 million In Romania, we delivered a strong Spring revolutions, we further accelerated 2011: $70 million: 2010: $66 million.
performance with sales up 19% to our growth with sales up 3%.
Our largest Other Emerging ROW $161 million 2011: $154 million: 2010: markets were South Africa, Saudi Arabia Sales in Other Emerging ROW were at at $119 million, largely as a result of sales and the Gulf States.
$2,152 million 2011: $2,290 million: 2010: of Atacand increasing by 34%, Seroquel XR $2,096 million, with increased sales in Latin increasing by 41%, Crestor increasing America, Egypt, Maghreb, Saudi Arabia by 10% and Symbicort increasing by and the Gulf States balanced by reduced 4%.
In Turkey, a decrease in sales to sales in South Africa and Israel.
$252 million 2011: $297 million: 2010: $304 million reected the additional price and prescription controls imposed by the Turkish government in late 2011.
AstraZeneca Annual Report and Form 20-F Information 2012 73
